Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
Status:
Completed
Trial end date:
2020-03-15
Target enrollment:
Participant gender:
Summary
A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production
and plasma glucagon levels in patients with end-stage renal disease (ESRD)